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What’s new?  
How the endometriotic microenvironment contributes to the initiation and progression of 
endometrioid ovarian adenocarcinoma remain poorly understood. We profiled carefully curated 
specimens of ovarian endometrioid adenocarcinoma with concurrent endometriosis and found 
that tumors from women with concurrent evidence of endometriosis were molecularly distinct 
from those without endometriosis. Inflammatory, NFkB, RAS, and BMP signaling pathways 
were specifically activated in tumors from women with evidence of endometriosis. These 
molecular differences may become targets for future personalized therapy.   
 
Endometriosis increases the risk of certain cancers, and yet having endometriosis at the time 
cancer is diagnosed seems to improve the chance of a good outcome. These authors 
investigated how endometriosis affects the gene expression profile of ovarian endometrioid 
adenoma (OEA). Tumors from women with endometriosis, they found, had a distinct genetic 
signature compared to OEA in women without endometriosis. Some 682 genes they found 
differentially expressed, depending on the presence or absence of endometriosis. The signaling 
pathways affected, including NFkB, RAS, and BMP, might provide promising therapeutic 
targets. 
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ABSTRACT (Unstructured; MAX 250 words/currently 250)  
Women with endometriosis, a benign growth of endometrial tissue outside the uterine 
cavity, are at increased risk of specific histotypes of epithelial ovarian cancer, such as ovarian 
endometrioid adenocarcinoma (OEA). Women with OEA who have endometriosis at time of 
surgical staging demonstrate improved clinical prognosis compared to women with OEA without 
evidence of endometriosis. However, the molecular contributions of the endometriotic tumor 
microenvironment to these ovarian cancers remain poorly understood. As a starting point, we 
utilized a platform for genome-wide transcriptomic profiling to compare specimens of OEA from 
women with and without concurrent endometriosis and benign reproductive tract tissues, 
including proliferative endometrium and typical and atypical endometrioma samples (n=20). 
Principle component analysis revealed distinct clustering between benign and malignant samples 
as well as malignant samples with and without concurrent endometriosis. Examination of gene 
signatures revealed that OEA with concurrent endometriosis contained a unique molecular 
signature compared with OEA without concurrent endometriosis, distinguished by 682 unique 
genes differentially expressed (fold change < or >1.5, P<0.01). Bioinformatic analysis of these 
differentially expressed gene products using Ingenuity Pathway Analysis revealed activation of 
NFkB signaling, an inflammatory signaling pathway constitutively active in endometriosis. 
DAVID functional annotation clustering further revealed enrichment in RAS signaling as both 
cytoskeleton organization and GTPase regulator activity relied heavily on RAS protein signal 
transduction. Gene set enrichment analysis highlighted immune and inflammatory nodes 
involved in OEA with concurrent endometriosis. These observations provide novel resources for 
understanding molecular subtleties potentially involved in OEA within the context of the 
endometriotic tumor microenvironment.  
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Introduction 
 Most ovarian cancers arise from cells that are not normally found in the ovary1. For 
example, ovarian endometrioid adenocarcinoma (OEA) is thought to arise from secretory 
epithelial cells2 of the eutopic endometrium or endometriosis. Endometriosis is a hormonally 
responsive, pathologic growth of endometrium outside the uterus (i.e., ectopic location), 
frequently discovered as a benign cyst on the ovary called an endometrioma3. The presence of 
endometriosis, itself a benign disease, increases the risk of ovarian endometrioid and clear-cell 
adenocarcinoma up to 8.9 fold, depending on genetic admixture and environmental exposures4-6. 
Clinically, studies suggest that co-occurrence of endometriosis with ovarian cancer is associated 
with an improved prognosis7-9. Although Dr. John Sampson first hypothesized the malignant 
potential of endometriosis in 192510, the relationship between endometriosis and ovarian cancer 
is still being deciphered. Previous reports have identified a limited number of oncogenes or 
tumor suppressors that may be involved in the pathogenesis of OEA3. Mutations alone cannot 
explain the clinical and phenotypic differences, and thus, the endometriotic tumor 
microenvironment may play a significant role in the pathogenesis of OEA2. However, specific 
molecular contributions of the endometriotic tumor microenvironment to OEA remain poorly 
understood. 
At least in part, insight into the molecular contributions of endometriosis to OEA remains 
limited due to the rarity of well-characterized tissue samples. OEA accounts for fewer than 10% 
of all epithelial ovarian cancers11, 12, and less than 43% of women with OEA have endometriosis 
at time of staging13-16. Consequently, few existing studies have focused on molecular features 
unique to OEA with concurrent endometriosis. To study the unique molecular contributions of 
endometriosis in OEA, we have directly compared the transcriptome of OEA with and without 
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concurrent endometriosis with the goal of identifying previously unappreciated aspects of this 
disease. Our results provide insight into the critical gene networks important in OEA in the 
context of the endometriotic tumor microenvironment.  
 
Materials and Methods 
Collection of human tissues and meta-data 
After expedited IRB approval, de-identified flash-frozen specimens were obtained from 
the Human Tissue Acquisition and Pathology Core of the Dan L. Duncan Comprehensive Cancer 
Center, the Gynecologic Tissue Biorepository for the Department of Obstetrics and Gynecology 
at Baylor College of Medicine, and the Gynecologic Oncology Group (GOG). Histopathologic 
and demographic data were abstracted from de-identified surgical pathology reports for each 
study subject. Benign samples were obtained as previously described17.  
RNA preparation and Hybridization 
 Total RNA was extracted using the mirVana kit (Applied Biosystems, Foster City, CA). 
Only RNA samples that passed strict quality control using an Agilent 2100 bioanalyzer (Agilent 
Technologies, Palo Alto, CA) underwent whole genome expression profiling using Illumina's 
Human WG-6 version 3.0 BeadChip, which contains 48,804 probes covering 27,455 genes. This 
was performed as a fee for service at the Texas Children’s Cancer Genomics and Proteomics 
Core Lab. 
Bioinformatical Analysis 
 Raw CEL microarray data was processed and normalized by Bioconductor R package 
“beadarray”18 under default parameter setting. Considering the sample size of the experiment, 
differential gene expression analysis was conducted by using empirical Bayes-based tests in the 
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Bioconductor R package “siggenes”19. Differential gene expression was determined by a 
significant cutoff with P-value <0.001 and log-fold change <-0.5 or >0.5. To fully identify the 
biological pathways and processes related to the differentially expressed genes, we conducted 
pathway enrichment analysis by using (1) Ingenuity Pathway Analysis (IPA), (2) functional 
clusters in DAVID20, 21, and (3) a hypergeometric test-based approach against gene sets from 
MsigDB (molecular signatures database)22, with a significance cutoff P <0.05. Multidimensional 
scaling (MDS) plot was made by the top two principle components derived from expression 
profile of all probes. 
Bioinformatics Analysis of Public Datasets 
 Normalized gene expression profiles of data sets GSE7305, GSE5108, GSE11691, and 
GE23339 were retrieved from GEO database17, 23-25. Due to the relatively large number of 
samples in each database and the fact that each of these four data sets were generated using 
different microarray platforms, we used the non-parametric Mann Whitney test for differential 
gene expression analysis, with P<0.01 as the cutoff for significance. Significance of overlap of 
the differentially expressed genes identified in different data sets was tested by Fisher’s exact test. 
Quantitative PCR for mRNA 
 RNA was treated with Turbo DNase (Life Technologies, Foster City, CA). DNase-treated 
RNA (1000 ng) was reverse-transcribed in a 50-µL-reaction volume with Superscript III (Life 
Technologies) and random primers (Life Technologies). Samples were diluted to 100 µL and 
two µL was used for each quantitative real-time PCR (QPCR) reaction. QPCR was performed 
using a QuantStudio 3 real-time PCR system, inventoried TaqMan gene expression assays 
(Supplemental Table 1), and TaqMan universal PCR master mix II (Life Technologies) in 10-
µL-reaction volume with reaction conditions as published17. Each sample was analyzed in 
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duplicate and a no template control sample was included on each plate for each primer-probe set. 
Expression of 18S RNA was used as an endogenous control. The relative quantity (RQ) of 
individual transcripts was calculated using the 2–ΔΔCT method26,  plotted as mean ± SEM, with a 
Student's t test used to generate P values for statistical significance.  
 
Results 
OEA samples with concurrent endometriosis are molecularly distinct. 
Since OEA is a rare histotype of epithelial ovarian cancer11, 12 and a majority of women 
with OEA do not have endometriosis at time of staging13-16, we used multiple tissue banks to 
obtain adequate number of samples for analysis. Supplemental table 2 details the metadata for 
each sample including clinical demographics, tissue source, and RNA quality control metrics. 
Table 1 summarizes clinical and pathological characteristics. Women without OEA were 
significantly (P=0.0001) younger [median: 38 years, range (25-48)] than women with OEA 
[median 52 years, range (37-76)]. In women with OEA, women without concurrent 
endometriosis had a trend towards higher stage disease (P=0.051) but did not have a significant 
difference in grade. Thus, the samples used for molecular studies are clinically similar.  
We performed genome-wide transcriptome profiling on RNA isolated from specimens 
(n=20) collected from endometriomas (n=4), endometriomas with epithelial atypia (n=3), 
proliferative endometrium (n=4), OEA without endometriosis (n=4), and OEA with concurrent 
endometriosis (n=5). Considering the mix of pathologies (e.g., benign and malignant), tissue 
types (e.g., endometrium, cancer, endometrioma cyst wall), number of experimental batches 
(e.g., only six samples on a single microarray), multiple sources of specimens (e.g., tissue bank), 
we could not adequately conduct batch effect removal.  
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Small total RNA abundance may cause a bias in microarray data, in particular Illumina 
microarrays27, 28. Our analysis of the whole dataset suggests the samples with too small amount 
of total RNA are more like outliers compared to the other samples of the sample disease class. 
Hence, the samples with total RNA amount less than 30 µg at time of RNA isolation from tissue 
were excluded from the final microarray analysis (Supplemental Figure 1). To validate this 
exclusion analysis, we compared our datasets to published datasets. We compared our benign 
datasets (e.g., endometrioma and proliferative endometrium) with four publicly available and 
previously published data sets17, 23-25. We found that the differentially expressed genes in 
endometriomas versus endometrium (Supplemental Tables 3 and 4) were highly enriched 
among differentially expressed genes identified by other published datasets (pooled P-value 
<1E-30) (Supplemental Table 5). Only one previously published dataset exists for OEA with 
concurrent endometriosis, but the data are not publically available29. Therefore, our datasets for 
OEA with and without concurrent endometriosis represent unique publically available research 
datasets.  
Next, gene expression profiles (n=15) were evaluated using principal component analysis 
(Figure 1). Graphical representation of principal components (PC) 1 and 2 shows that gene 
expression profiles from malignant samples clustered separately from benign samples (Figure 
1A). Graphical representation of PC1 and PC3 shows that OEA samples with endometriosis 
cluster separately from those without endometriosis (Figure 1B). Thus, at a global level, OEA 
with endometriosis is molecularly distinct from OEA without endometriosis. 
To identify the biological characteristics of each principal component, we conducted 
pathway enrichment analysis on the 200 genes that are most positively/negatively associated 
with the loading of each principal component (Supplemental Table 6). Glycolysis (P=0.04), 
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pyruvate (P=0.019), cysteine (P=0.013), and alanine/glutamate (P=6E-5) metabolism; P53 
(P=0.04), WNT (P=0.04), and Ephrin receptor (axon guidance, P=0.004) signaling; and RNA 
polymerase (P<0.01) and DNA repair (P=0.002) pathways are negatively correlated with PC1. 
Extracellular region and cell adhesion related pathways including cell adhesion (P=2E-12), 
cytokine-cytokine receptor (P=0.01), extracellular matrix (ECM) receptor interaction (P=5E-10), 
vascular endothelial growth factor (VEGF, P=0.001), hypoxia-inducible factor 1-alpha (HIF1A, 
P=0.04), and glycoprotein metabolic (P=8E-13) pathways are positively correlated with PC1. 
Cell cycle (P=4e-5), DNA replication (P=3E-5), and glycolysis (P=0.04) pathways are 
negatively correlated with PC2. Apoptosis (P=0.001), cytokine-cytokine receptor (P=0.01), 
coagulation (P=7E-08), extrinsic inflammation (P=0.001), cell-matrix adhesion (P=7E-05), and 
chemokine signaling (P=0.01) pathways are positively associated with PC2. Transforming 
growth factor beta (TGFβ, P=0.01) and cell cycle (P=0.01) pathways are negatively associated 
with PC3. Immune response (P=2E-4), cytokine signaling in immune system (P=0.002), T cell 
signaling (P=0.02), and interleukin (IL1, IL6) signaling pathways (P<0.01) are positively 
associated with the PC3 (Supplemental Table 6).  
Such pathway associations suggest that OEA with and without endometriosis are most 
similar in terms of glycolysis and P53 and WNT signaling (PC1) and cell cycle (PC2), while 
proliferative endometrium and endometrioma are most similar in terms of pathways involved in 
dysregulated cell adhesion, extracellular matrix (PC1), and an inflammatory response (PC2, 
Figure 2A). Figure 2B shows a distinct difference between OEA with and without 
endometriosis (PC1 and PC3). This distinction is mediated by PC3 with significant contributions 
from TGFβ, cell cycle, and immune response (Supplemental Table 6). Our pathway analysis of 
the PC-associated genes suggests that OEA with endometriosis has increased TGFβ signaling 
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compared to OEA without endometriosis. OEA without endometriosis, endometrioma, and 
proliferative endometrium have similar level of dysregulated immune and inflammatory response. 
A close distance between atypical endometrioma and OEA without endometriosis relies heavily 
on this similarity of dysregulated immune and inflammatory response. Detailed lists of the genes 
and their enriched pathways are given in Supplementary Table 6.  
We directly compared gene expression profiles of OEA samples without endometriosis 
(n=4) to OEA with concurrent endometriosis (n=3) to determine molecular distinctions between 
these histologically similar tumors (log-fold change > 0.5 or < -0.5, P<0.01; Supplemental 
Tables 7 and 8). We discovered 1022 probes differentially expressed, with 239 probes 
downregulated and 783 probes upregulated. Of these, 526 mapped IDs corresponding to 497 
unique genes were upregulated and 206 mapped IDs corresponding to 184 unique genes were 
downregulated in OEA with concurrent endometriosis compared to OEA without endometriosis. 
Figure 2 shows the volcano plot of differentially gene expression analysis and heat map of 
differentially expressed genes. 
 
Molecular networks selectively dysregulated in OEA with concurrent endometriosis.  
To explore potentially impactful pathways and processes related to the differentially 
expressed genes, we conducted pathway enrichment analysis by using IPA, DAVID20, 21, and 
gene set enrichment analysis22. From IPA, the most statistically significant canonical pathways 
with a positive Z-score were leukocyte extravasation signaling (P=5.13E-05) and acute phase 
response signaling (P=4.07E-04), two pathways involved in inflammation. The most statistically 
significant canonical pathways with negative Z-scores were gonadotropin releasing hormone 
(GNRH) signaling (P=1.20E-03) and bone morphogenetic protein (BMP) signaling (P=6.17E-
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03). For these four statistically significant canonical signaling pathways, Table 2 lists the 
differentially expressed genes and fold-change. Figure 3 depicts a waterfall plot of the 
statistically significant canonical pathways (P<0.05) dysregulated in OEA with concurrent 
endometriosis. Out of those 35 canonical pathways, 25 have contributions from nuclear factor 
kappa-light-chain-enhancer of activated B cells (NFkB) signaling (Supplemental Table 9). 
Overlaying this gene list on the molecular mechanisms of cancer canonical pathway shows 
activation of RAS signaling (Supplemental Figure 2). DAVID functional clustering analysis 
identified 153 and 92 functional clusters enriched by the up- and downregulated genes, 
respectively. From DAVID in support of RAS signaling, the top upregulated functional clusters 
included RAS association, protein kinase, response to stimulus, immune response, and regulation 
of cell development. The top downregulated functional clusters included endoplasmic reticulum, 
response to hormone stimulus, anti-apoptosis, and cell migration and adhesion. A complete list 
of the identified functional clusters is given in Supplementary Tables 10 and 11. Pathway 
enrichment test against MsigDB canonical pathways identified 117 pathways enriched by the 
upregulated genes, including interleukin signaling (P=2E-04), RAS homolog family member A 
(RHOA) regulation (P=0.001), C-X-C motif chemokine receptor 4 (CXCR4) signaling 
(P=0.003), and kinase activity (P=2E-04), pathways that are related to immune and 
inflammatory responses. We also identified 325 pathways enriched by the downregulated genes, 
including integrin (P=1.21E-06), cell-cell adhesion (P=1.6E-05), cell proliferation (P=1.4E-04), 
NOTCH (P=2.3E-04), WNT (P=3.8E-04), and hypoxia inducible factor 1 alpha subunit (HIF1A) 
(P=4E-04) signaling pathways. A complete list of the MsigDB enriched pathways is provided in 
Supplementary Tables 12 and 13.  
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 We validated the expression of selected individual genes using real-time QPCR with a 
focus on genes in unique molecular pathways in OEA or genes not studied in ovarian cancer 
(Figure 4). Most of the genes followed a similar trend in expression via QPCR compared to 
microarray analysis. Plasminogen activator, urokinase (PLAU) was 3.8-fold upregulated on 
microarray analysis and followed similar direction of regulation in QPCR validation studies (1.6-
fold change, P=0.008). There was no change in gene expression of the PLAU receptor (PLAUR), 
although studies suggest that PLAUR serum protein levels may play diagnostic roles for women 
with adnexal masses30. Gene members involved in BMP signaling (Table 2), including CREB 
binding protein (CREBBP), protein kinase cAMP-activate catalytic subunit beta (PRKACB), and 
mitogen activated protein kinase 13 (MAPK13), showed a statistically significant difference in 
gene expression compared to samples without endometriosis. A similar trend in appropriate 
direction was observed for SMAD family member 6 (SMAD6) and nuclear factor kappa B 
subunit 2 (NFKB2). Bone morphogenetic protein 8B (BMP8B) showed a 4-fold downregulation 
that was statistically significant (P=0.002) but in opposite direction of microarray (2.3-fold 
upregulation). In silico inhibition of BMP leads to no predicted downstream signaling 
differences (Supplemental Figure 3). Although catenin beta 1 (CTNNB1) was not a statistically 
significant change, it was downregulated in QPCR studies similar in direction to microarray 
results. P21 (RAC1) activated kinase 2 (PAK2) has shown to decrease migration of ovarian 
cancer cells in vitro31. PAK2 showed a 5.3-fold downregulation in microarray analysis and 2.2-
fold change downregulation by QPCR (P=0.0009). The gene expression changes were validated 
by independent QPCR.  
 
Discussion 
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Ovarian cancer is the seventh most common cancer in women, and the eighth leading 
cause of cancer-related death worldwide, claiming over 151,000 lives in 201232. Currently, 
standard-of-care therapy treats nearly all women with ovarian cancer similarly, even though 
studies have shown that individual histotypes of ovarian cancer (i.e., high-grade serous, 
endometrioid, clear-cell, and mucinous) are molecularly distinct and likely arise from a unique 
cell of origin1. Thus, there is a clinical need to understand the key molecular drivers of cancer 
subsets such as those arising from endometriosis, which may drive treatment recommendations. 
Currently, whole genome sequencing analysis of ovarian cancer samples allows stratification 
into histotypes, including sub-classification of OEA into tissues that are microsatellite stable and 
those with microsatellite instability33. While large amounts of genomic data have been generated 
based on histotype, there is limited information regarding the molecular contribution of the 
endometriotic tumor microenvironment on OEA. While this subtle pathologic diagnosis is often 
overlooked in research studies, the improvement of outcomes of women with endometriosis at 
time of ovarian cancer staging is not7-9. Therefore, the molecular contributions of the 
endometriotic tumor microenvironment may affect the overall tumor biology.  
We have performed a comprehensive assessment of gene expression signatures in OEA 
from women with concurrent endometriosis. Our data suggests that OEA from women with 
endometriosis has a distinct molecular signature when compared to OEA from women without 
endometriosis. We have identified signaling pathways that appear to uniquely contribute to the 
pathogenesis of this subset of ovarian cancers with inflammatory, NFkB, RAS, and TGFβ 
signaling pathways playing a significant role. In support of our data, KRAS oncogenic mutations 
have been discovered in 29% of ovarian cancers with concurrent endometriosis34. Transgenic 
mice expressing oncogenic Kras develop both endometriosis-like lesions and OEA when a 
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conditional Pten deletion is introduced in the ovarian bursa35. However, activated signaling 
cascades through RAS have not been specifically described until this report. The TGFβ 
superfamily has been implicated in ovarian cancers, particularly sex cord-stromal tumors36-40, but 
not specifically in epithelial ovarian cancers. Thus, these results support further study into the 
molecular contributions of the endometriotic tumor microenvironment.  
To date, only one study has used whole transcriptome microarray analysis to evaluate 
specimens of normal ovary, endometriomas, and OEA with and without concurrent 
endometriosis29. Results of this work revealed only a small group of cytokines dysregulated in 
OEA with concurrent endometriosis and endometriomas, consistent with the known 
inflammatory milieu of endometriosis. While those results suggest that the endometriotic tumor 
microenvironment may contribute to OEA, we were unable to compare our results to those 
datasets directly, as they are not publically available. Nonetheless, our current observations build 
on this earlier work by expanding and identifying additional gene products and signaling 
pathways that may contribute to the distinct clinical behaviors associated with subsets of patients 
diagnosed with OEA with concurrent endometriosis. 
A strength of the current study is that the specimens of OEA used in our study are 
histologically similar, containing >80% tumor cells, without mixed histology, and all OEA with 
concurrent endometriosis are confirmed by histopathology reports. Similar to other studies7, 
OEA without endometriosis represented a trend towards higher stage disease (P=0.051). While 
there was no significant difference in high-grade disease, our studies were not powered for this 
analysis (Table 1). However, due to our strict inclusion criteria, only a small number of tissue 
samples were available, reflecting the rarity of OEA and OEA associated with endometriosis11-16. 
Although OEA with and without concurrent endometriosis may arise from endometriosis1, recent 
A
cc
ep
te
d
 A
rt
ic
le
This article is protected by copyright. All rights reserved.
 17 
studies show that OEA samples may be stratified into distinct biological features within the OEA 
histotype based on the somatic genome33.  
Our study is limited by the use of relative insensitive microarray technology compared to 
other technologies now available for whole exome profiling. For example, a key player in OEA, 
AT-rich interaction domain 1A (ARID1A)14, 41 is not represented on this microarray platform. 
The validity of our observations is supported by the fact that we were able to validate them by 
QPCR in a second, independent cohort of well-characterized tissue samples. Nonetheless, future 
studies with larger sample sizes on next-generation sequencing platforms may highlight 
additional signaling pathways and help to provide an even more complete picture of OEA and 
the molecular contributions of endometriosis.  
The molecular mechanism of transformation of endometriosis or atypical endometriomas 
into malignant ovarian cancers is being actively studied. While mutations in the oncogene, 
KRAS, and ARID1A have been frequently documented in endometriosis-associated ovarian 
cancers42, these mutations are frequently discovered in deeply infiltrating implants of 
endometriosis that do not typically progress to ovarian cancer43. Thus, the correlation between 
genotype and clinical phenotype still needs to be determined42. Clinically, it is thought that 
women with long-term untreated endometriosis are at highest risk of developing ovarian 
cancer42. For example, the protection of combined oral contraceptive therapy on ovarian cancer 
risk is more robust for women with endometriosis [odds ratio 0.21 (0.08-0.58, P=0.003) 
compared to non-endometriosis population 0.47 (0.37-0.61, P<0.001)]44. Both endometriosis and 
ovarian cancer are hormone responsive diseases45, 46 and thus while the overall steroid hormone 
suppression offered by combined oral contraceptives makes logistical sense, the actual molecular 
mechanism has not been elucidated and likely involves molecular, genetic, and hormonal factors.  
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An interesting target within the context of the endometriotic tumor microenvironment is 
the contribution of NFkB to OEA. A majority of our canonical signaling pathways had 
significant contributions of NFkB (Supplemental Table 9). Studies have shown that 
endometriosis progression relies on constitutive active NFkB, and NFkB signaling pathways are 
potential targets for non-hormonal therapies for endometriosis47, 48. NOTCH, WNT, and HIF1A 
signaling pathways were also significantly enriched. Whether these signaling cascades are 
downstream of NFkB signaling cascades or if they arise independent of NFkB signaling from the 
cell’s response to the endometriotic tumor microenvironment are unknown. Deeper 
understanding on the role of NFkB signaling cascades, inflammation, and even 
microenvironmental stress in OEA with concurrent endometriosis may drive novel treatment 
recommendations with future studies. 
As an additional area under study, the origin of ovarian cancer is still relatively 
controversial. While some high-grade serous ovarian cancers are thought to arise from the 
malignant transformation of fimbria of the fallopian tube with subsequent early metastasis to the 
ovary1, 49, others may arise from the ovary itself1, 50. OEA is thought to arise from secretory 
epithelial cells that are frequently found in eutopic endometrium and ectopic endometriomas2. 
Further, the cell of origin may predict aggressive disease. For example, high-grade OEA without 
endometriosis may develop from the secretory epithelial cells of the eutopic endometrium2 and 
already have a metastatic phenotype by the time it is discovered42. On the other hand, OEA with 
concurrent endometriosis may develop from secretory epithelial of endometriomas and represent 
a non-metastatic phenotype42. While our results examine the gene expression differences 
between OEA with and without endometriosis, these differences may be from the unique 
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endometriotic tumor microenvironment or from the unique cell of origin. Due to low frequency 
of these clinical samples, additional model systems may be necessary to answer these questions.  
Our studies delineate key molecular pathways in OEA with concurrent endometriosis. 
Future studies should be undertaken to detail the role of inflammation including the contribution 
of constitutive active NFkB in endometriosis and RAS and BMP signaling in the clinical features 
of OEA. We believe that future studies targeting key signaling pathways may have implications 
for novel treatment. Thus, understanding the molecular features of OEA with concurrent 
endometriosis may have an impact on a significant number of women’s lives. 
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Figure 1: Distinct molecular profiles of OEA with concurrent endometriosis. A, Principle 
component analysis of malignant samples (dotted line) cluster separately from benign samples 
(solid line), using principle component (PC) 1 and PC2. B, Separation of malignant samples into 
with concurrent endometriosis (dotted line) and without concurrent endometriosis (dashed line), 
using PC1 and PC3 (B). Smaller circle, atypical endometriosis samples.  
 
Figure 2: Differential expression of genes in OEA with and without endometriosis. A, Volcano 
plot representation of transcripts overexpressed (red), similarly expressed (black), and under 
expressed (green) in samples with endometriosis compared to those without concurrent 
endometriosis. B, Heat map representation of transcripts overexpressed blue and under expressed 
red in samples with endometriosis compared to those without concurrent endometriosis (P<0.01, 
log-fold change <-0.5 or >0.5). Dendrogram of hierarchical clustering. Rows, gene transcripts, 
columns, profiled samples. 
 
Figure 3: Waterfall plot of significant canonical pathways dysregulated in OEA with 
endometriosis. Pathway analysis from IPA was used to predict canonical pathways and generate 
P-values. Only pathways with Z-scores were used for analysis.  
 
Figure 4: Comparison of gene expression by microarray analysis and QPCR. QPCR data was 
normalized to 18s rRNA. All microarray genes are statistically significantly different (P<0.01). 
Relative fold change for QPCR was determined as expression in OEA with endometriosis to 
without endometriosis. **, P<0.01; *, P<0.05.  
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Supplemental information 
Supplemental Figure 1: Flow diagram of samples in microarray analysis. Strikethrough indicates 
samples that were removed from final analysis, based on total RNA<30µg.  
 
Supplemental figure 2: Molecular mechanism of cancer canonical pathway dysregulated in OEA 
with endometriosis. Overlay shows predicted signaling activation (orange) and inhibition (blue). 
Note predicted activation of RAS (left side) through inhibition of RAS-GTPase accelerating 
protein (GAP), leading to predicted activation of MAPK signaling including cyclin D1 (CCND1) 
activation.   
 
Supplemental Figure 3: Predicted signaling effects of BMP8B on BMP signaling pathway. A, 
BMP signaling pathway with high expression of BMP8B as indicated by microarray analysis. B, 
in silico predicted signaling effects with inhibition of BMP8B. Note little difference in 
downstream signaling. Orange shading, predicted activation; blue shading, predicted inhibition.  
 
List of Supplemental Tables: 
Supplemental Table 1: TaqMan assay IDs for assays used in QPCR 
Supplemental Table 2: Details of clinical samples used in study 
Supplemental Table 3: Endometrioma down genes 
Supplemental Table 4: Endometrioma up genes 
Supplemental Table 5: Comparison of endometrioma differentially expressed genes to published 
studies 
Supplemental Table 6: Multiple tabs containing contributions of each principle component 
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Supplemental Table 7: OEA with concurrent endometriosis down genes 
Supplemental Table 8: OEA with concurrent endometriosis up genes 
Supplemental Table 9: Listing of IPA canonical pathways unique to OEA with concurrent 
endometriosis, highlighting NFkB pathways.  
Supplemental Tables 10 and 11: List of DAVID functional clusters enriched by the differentially 
expressed genes in OEA with concurrent endometriosis versus. 
Supplemental Tables 12 and 13: List of MsigDB canonical pathways enriched by the 
differentially expressed genes in OEA with concurrent endometriosis. 
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Characteristic Benign (n=11) P -value
Age, y 38 (25-48) 0.0001
With Endometriosis 
(n=10)
Without 
endometriosis 
(n=14)
Age, y 53.2 (40-73) 52 (37-76) 0.952
Hawkins 11 (100) 1 (10) 0 (0)
Ob/Gyn 0 (0) 2 (20) 0 (0)
GOG 0 (0) 7 (70) 10 (71.4)
DLDCC 0 (0) 0 (0) 4 (28.6)
Sertoli leydid cell 
tumor 1 (9.1) 0 (0) 0 (0)
Mature cystic 
teratoma 1 (9.1) 0 (0) 0 (0)
Benign serous 
cystadenoma 0 (0) 1 (14.3) 0 (0)
Ovarian 
endometrioid 
adenocarcinoma 0 (0) 9 (100) 14 (100)
6 (60) 4 (28.5) 0.124
4 (40) 10 (71.4)
4 (40) 1 (7.1) 0.051
6 (60) 13 (92.9)
Endometrioma 7 (63.6) 5 (55) 0 (0)
Endometrioma 
with atypia 3 (42.9) 1 (20) 0 (0)
Endometrial 
hyperplasia 1 (9.1) 2 (20) 1 (7.1)
Adenomyosis 0 (0) 5 (50) 3 (21.4)
Endometrial 
adenocarcinoma 0 (0) 1 (10) 1 (7.1)
Chronic 
endometritis 2 (18.2) 0 (0) 0 (0)
Proliferative 
endometrium 8 (72.7) 2 (20) 2 (14.3)
Atrophic 
endometrium 0 (0) 3 (30) 4 (28.6)
Uterine 
leiomyoma 4 (36.4) 6 (60) 3 (21.4)
Unknown 0 (0) 2 (20) 4 (28.6)
 Table 1: Clinical characteristics of women whose samples were used in study
Malignant (n=24)
Bank source
Adnexal pathology
Grade 1-2
53 (37-76)
 a Values are given as median (range) or number (percentage)
Stage I 
Stage II or greater
Uterine pathology
Grade 3
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Table 2: Dysregulated signaling pathways 
Symbol Name P-value 
log-
fold 
change 
Leukocyte extravasation signaling 
ACTG2 
actin, gamma 2, 
smooth muscle, 
enteric 0.00327 -2.026 
CLDN20 claudin 20 0.000192 0.704 
CTNNB1 catenin beta 1 0.00735 -1.203 
CTTN cortactin 0.00754 -0.907 
CXCL12 
C-X-C motif 
chemokine ligand 12 0.0088 -1.222 
ITGA6 
integrin subunit 
alpha 6 0.00597 -0.529 
JAM2 
junctional adhesion 
molecule 2 0.00725 -1.117 
MAPK13 
mitogen-activated 
protein kinase 13 0.00525 -0.725 
MMP8 
matrix 
metallopeptidase 8 0.00105 0.55 
NCF4 
neutrophil cytosolic 
factor 4 0.00168 0.521 
PIK3CD 
phosphatidylinositol-
4,5-bisphosphate 3-
kinase catalytic 
subunit delta 0.00451 0.644 
PRKCZ 
protein kinase C 
zeta 0.0012 0.634 
PTK2B 
protein tyrosine 
kinase 2 beta 0.00077 0.587 
RAPGEF3 
Rap guanine 
nucleotide exchange 
factor 3 0.00819 1.184 
SPN sialophorin 0.0027 1.031 
TXK TXK tyrosine kinase 0.00251 1.048 
VAV2 
vav guanine 
nucleotide exchange 
factor 2 0.00514 0.767 
VCAM1 
vascular cell 
adhesion molecule 1 0.00603 -0.702 
Acute phase response signaling 
AHSG 
alpha 2-HS 
glycoprotein 0.000575 0.677 
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AMBP 
alpha-1-
microglobulin/bikunin 
precursor 0.000207 0.569 
C1S complement C1s 0.00659 -0.933 
IKBKB 
inhibitor of nuclear 
factor kappa B 
kinase subunit beta 0.00135 0.683 
IL6ST 
interleukin 6 signal 
transducer 0.00536 -0.975 
ITIH4 
inter-alpha-trypsin 
inhibitor heavy chain 
family member 4 0.00195 0.811 
MAPK13 
mitogen-activated 
protein kinase 13 0.00525 -0.725 
NFKB2 
nuclear factor kappa 
B subunit 2 0.0028 0.537 
PIK3CD 
phosphatidylinositol-
4,5-bisphosphate 3-
kinase catalytic 
subunit delta 0.00451 0.644 
RBP5 
retinol binding 
protein 5 0.00174 0.525 
RBP7 
retinol binding 
protein 7 0.00214 -0.831 
SERPING1 
serpin family G 
member 1 0.00916 1.327 
SOCS4 
suppressor of 
cytokine signaling 4 0.00382 -0.566 
TRADD 
TNFRSF1A 
associated via death 
domain 0.00184 -0.93 
GnRH signaling 
CREBBP 
CREB binding 
protein 0.000972 -1.138 
DNM1 dynamin 1 0.00947 0.532 
ITPR1 
inositol 1,4,5-
trisphosphate 
receptor type 1 0.00116 -1.111 
MAP3K12 
mitogen-activated 
protein kinase 
kinase kinase 12 0.00396 0.688 
MAPK13 
mitogen-activated 
protein kinase 13 0.00525 -0.725 
NFKB2 
nuclear factor kappa 
B subunit 2 0.0028 0.537 
PAK2 
p21 (RAC1) 
activated kinase 2 0.00172 -1.636 
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PLCB4 
phospholipase C 
beta 4 0.000554 -1.434 
PRKACB 
protein kinase 
cAMP-activated 
catalytic subunit beta 0.00829 -0.876 
PRKAG2 
protein kinase AMP-
activated non-
catalytic subunit 
gamma 2 0.00125 -0.801 
PRKCZ 
protein kinase C 
zeta 0.0012 0.634 
PTK2B 
protein tyrosine 
kinase 2 beta 0.00077 0.587 
BMP signaling 
BMP8B 
bone morphogenetic 
protein 8b 0.00388 0.813 
CREBBP 
CREB binding 
protein 0.000972 -1.138 
MAPK13 
mitogen-activated 
protein kinase 13 0.00525 -0.725 
NFKB2 
nuclear factor kappa 
B subunit 2 0.0028 0.537 
PRKACB 
protein kinase 
cAMP-activated 
catalytic subunit beta 0.00829 -0.876 
PRKAG2 
protein kinase AMP-
activated non-
catalytic subunit 
gamma 2 0.00125 -0.801 
SMAD6 
SMAD family 
member 6 0.00198 0.886 
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